Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Twist Bioscience CorpTWST · Entity 3619 | President and COO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Twist Bioscience Corp
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,088 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 25,714 · Balance 185,088 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2020 Filed Aug 4, 2020 20:42 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 2,358 | $8.82 | $20,797.56 |
DisclosureSEC source: 0001214659-20-006766 · marketforms-49377.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 500 | $60.49 | $30,244.00 |
DisclosureSEC source: 0001214659-20-006545 · marketforms-49358.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,739 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $60.27 to $60.76 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 802 | $59.87 | $48,015.34 |
DisclosureSEC source: 0001214659-20-006545 · marketforms-49358.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,239 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $59.17 to $60.08 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 400 | $58.70 | $23,479.52 |
DisclosureSEC source: 0001214659-20-006545 · marketforms-49358.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,041 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $58.11 to $59.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 656 | $57.37 | $37,635.84 |
DisclosureSEC source: 0001214659-20-006545 · marketforms-49358.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,441 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $56.94 to $57.74 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,820 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0001214659-20-006242 · marketforms-49210.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,184 Underlying: Common Stock · 28,820 shares Expires 2028-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 10:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 28,820 | $26.66 | $768,341.20 |
DisclosureSEC source: 0001214659-20-006242 · marketforms-49210.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 10:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 820 | $48.47 | $39,741.55 |
DisclosureSEC source: 0001214659-20-006242 · marketforms-49210.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,277 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $48.10 to $48.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 10:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 15,264 | $47.03 | $717,916.29 |
DisclosureSEC source: 0001214659-20-006242 · marketforms-49210.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,097 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.66 to $47.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:52 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 11,336 | $46.69 | $529,271.04 |
DisclosureSEC source: 0001214659-20-006206 · marketforms-49209.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,361 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.66 to $46.73 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 02, 2020 Filed Jul 8, 2020 00:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,400 | $46.68 | $65,353.96 |
DisclosureSEC source: 0001214659-20-006178 · marketforms-49176.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,697 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 22, 2019. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.66 to $46.73 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 841 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-005944 · marketforms-49134.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,565 Underlying: Common Stock · 841 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 841 | $8.82 | $7,417.62 |
DisclosureSEC source: 0001214659-20-005944 · marketforms-49134.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 22:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 841 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-005282 · marketforms-48911.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,406 Underlying: Common Stock · 841 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 22:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 841 | $8.82 | $7,417.62 |
DisclosureSEC source: 0001214659-20-005282 · marketforms-48911.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 300 | $38.07 | $11,421.00 |
DisclosureSEC source: 0001214659-20-005282 · marketforms-48911.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,415 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.04 to $38.10 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 900 | $37.44 | $33,699.96 |
DisclosureSEC source: 0001214659-20-005282 · marketforms-48911.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,715 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $36.97 to $37.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:27 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 916 | $36.42 | $33,363.56 |
DisclosureSEC source: 0001214659-20-005282 · marketforms-48911.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,615 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $35.93 to $36.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2020 Filed May 28, 2020 23:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,207 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-005122 · marketforms-48900.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,247 Underlying: Common Stock · 4,207 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 26, 2020 Filed May 28, 2020 23:44 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 4,207 | $38.46 | $161,801.22 |
DisclosureSEC source: 0001214659-20-005122 · marketforms-48900.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 675 | $39.76 | $26,838.00 |
DisclosureSEC source: 0001214659-20-004966 · marketforms-48851.xml · nonDerivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,324 F5 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 100 | $41.07 | $4,107.00 |
DisclosureSEC source: 0001214659-20-004966 · marketforms-48851.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,999 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 599 | $40.21 | $24,087.35 |
DisclosureSEC source: 0001214659-20-004966 · marketforms-48851.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,099 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $40.04 to $40.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 20, 2020 Filed May 23, 2020 01:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,508 | $39.56 | $138,762.80 |
DisclosureSEC source: 0001214659-20-004966 · marketforms-48851.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,698 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $38.96 to $39.89 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 675 | $33.13 | $22,362.75 |
DisclosureSEC source: 0001214659-20-001746 · marketforms-47850.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,797 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-20-000576 · marketforms-47537.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,454 Underlying: Common Stock · 15,000 shares Expires 2027-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 15,000 | $8.82 | $132,300.00 |
DisclosureSEC source: 0001214659-20-000576 · marketforms-47537.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,994 | $23.04 | $138,095.77 |
DisclosureSEC source: 0001214659-20-000576 · marketforms-47537.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $22.74 to $23.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:34 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 9,006 | $22.18 | $199,735.07 |
DisclosureSEC source: 0001214659-20-000576 · marketforms-47537.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,466 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $21.77 to $22.69 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 22:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 15,000 | $25.27 | $378,975.00 |
DisclosureSEC source: 0001214659-19-007812 · marketforms-46872.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,472 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the aggregate of sales effected on the same day at different prices. F3 · balance_after: Represents the weighted average sales price per share. The shares sold at prices ranging from $24.32 to $25.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 663 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-19-007812 · marketforms-46872.xml · derivative · entry 5 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,454 Underlying: Common Stock · 663 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,875 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-19-007812 · marketforms-46872.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,875 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 01, 2016, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 663 | $8.82 | $5,847.66 |
DisclosureSEC source: 0001214659-19-007812 · marketforms-46872.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 6,875 | $5.95 | $40,906.25 |
DisclosureSEC source: 0001214659-19-007812 · marketforms-46872.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2019 Filed Nov 29, 2019 18:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 36,932 | $23.32 | $861,250.55 |
DisclosureSEC source: 0001214659-19-007463 · marketforms-46429.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,664 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $23.00 to $23.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 18:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-19-007463 · marketforms-46429.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Underlying: Common Stock · 33,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 01, 2016, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 18:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 33,000 | $5.95 | $196,350.00 |
DisclosureSEC source: 0001214659-19-007463 · marketforms-46429.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 23:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,868 | $22.85 | $88,383.80 |
DisclosureSEC source: 0001214659-19-007345 · marketforms-46381.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,596 Read SEC document |
| November 20, 2019 Filed Dec 19, 2019 22:32 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 3,868 | $22.85 | $88,383.80 |
DisclosureSEC source: 0001214659-19-007810 · marketforms-46879.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,866 F1 · balance_after: The amount of Common Stock beneficially owned following the reported transaction was previously misstated on the Reporting Person's original Form 4. Such beneficial ownership was also subsequently misstated on the Form 4 filed by the Reporting Person on November 29, 2019 following the transactions reported thereunder. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 22:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,311 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001209191-19-054663 · doc4.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,117 Underlying: Common Stock · 9,311 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 29, 2017, 15% of the shares subject to the option vest on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 22:50 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 9,311 | $8.82 | $82,123.02 |
DisclosureSEC source: 0001209191-19-054663 · doc4.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 20:54 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,753 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-19-054258 · doc4.xml · derivative · entry 4 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,875 Underlying: Common Stock · 4,753 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 20:54 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 26,398 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-19-054258 · doc4.xml · derivative · entry 3 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,398 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on February 2, 2016, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 20:54 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 4,753 | $5.95 | $28,280.35 |
DisclosureSEC source: 0001209191-19-054258 · doc4.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 20:54 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 26,398 | $1.19 | $31,413.62 |
DisclosureSEC source: 0001209191-19-054258 · doc4.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,236 | $22.43 | $139,884.70 |
DisclosureSEC source: 0001209191-19-054113 · doc4.xml · nonDerivative · entry 3 Finn Patrick John · CIK 0001755970 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,002 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $22.24 to $23.11 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 24, 2019 Filed Nov 6, 2019 02:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantEmployee Stock Option (right to buy) · Derivative | 39,710 | $0.00 Strike: $23.33 | $0.00 |
DisclosureSEC source: 0001209191-19-055407 · doc4.xml · derivative · entry 2 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,710 Underlying: Common Stock · 39,710 shares Expires 2029-10-23 F2 · derivative.exercise_date: 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. Read SEC document |
| October 24, 2019 Filed Nov 6, 2019 02:25 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 9,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055407 · doc4.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,734 F1 · shares: Represents a restricted stock unit award (the "RSU Award") that vests in installments, with 25% of the shares subject to the RSU Award vesting on October 24, 2020 and 1/16th of the shares subject to the RSU Award vesting on each quarterly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 100 | $23.68 | $2,368.00 |
DisclosureSEC source: 0001209191-19-054113 · doc4.xml · nonDerivative · entry 2 Finn Patrick John · CIK 0001755970 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,238 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 26,664 | $23.09 | $615,791.75 |
DisclosureSEC source: 0001209191-19-054113 · doc4.xml · nonDerivative · entry 1 Finn Patrick John · CIK 0001755970 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,338 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $22.67 to $23.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.